Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Abarceo Pharma

Portfolio company Abarceo Pharma

Abarceo Pharma is a spin out of Lund University Diabetes Center. The company is dedicated to developing novel therapeutics for type-2 diabetes based upon a deep molecular and genetic understanding of the disease.

Abarceo Pharma has identified a novel diabetes target and has elucidated the key to the revival of dysfunctional beta cells enabling a resetting of the beta cell to a functional and healthy state. Upon treatment, dysfunctional “lazy” beta cells are revived and able to respond to physiologic changes in blood glucose producing insulin naturally. This represents the first potential disease modifying treatment for type-2 diabetes which addresses the disease at the root and allows for durable and sustained glycemic control. 

 

Abarceo Pharma website

Abarceo Pharma

Develops novel therapeutics for type-2 diabetes. 

Founded by Albert Salehi and Claes Wollheim.

 

Portfolio company since 2018.